At WindMIL Therapeutics®, we are dedicated to our mission: Translating novel insights in bone marrow immunology into life-saving cell therapies for cancer patients.
The bone marrow has an important role in the immune system, acting as a reservoir of persistent immune cells generated as a response to foreign antigens. Our proprietary process creates a cellular product called MILs™ (Marrow Infiltrating Lymphocytes) that contains these activated tumor-targeting memory T cells.
T-cell therapy has long been viewed as a possible avenue for improved cancer treatment. Recent advances with CAR T therapies have shown substantial promise, yet broad application of T-cell therapies has been limited by:
- Heterogenous antigen expression (especially in solid tumors)
- Limited function and persistence
- Suboptimal trafficking of T cells into the tumor microenvironment
- Safety issues – cytokine release syndrome (CRS) and CAR T cell-related encephalopathy syndrome (CRES)
At WindMIL, we believe that Cell Source Matters™ in cell therapy and that T cells derived from the bone marrow provide a platform to address the current challenges in the field. WindMIL is the only company that can activate and expand this natural source of tumor-specific memory T cells that are:
- Patient specific
- Broadly antigen-specific
- Highly cytotoxic
- Highly persistent
We envision the treatment of any tumor beginning by first harnessing the intrinsic functionality of bone marrow-derived lymphocytes. We aim to leverage our deep understanding of the unique immunologic properties of the bone marrow to lead the way in cancer cell therapies, but also to fulfill our commitment to helping patients live a longer, healthier life.
Working at WindMIL, there’s a tangible sense of possibility and the desire to impact patients’ lives. We believe that acting with intent, according to our values, is the surest path to building a vibrant, exciting, collaborative and high-performing culture.